KRAS mutations are also notable in a variety of other cancer types including colon adenocarcinoma (50%), rectal adenocarcinoma (50%), lung adenocarcinoma (32%), small intestine adenocarcinoma (26%), cholangiocarcinoma (23%), plasma cell myeloma (18%), gallbladder carcinoma (16%), and anaplastic thyroid carcinoma (8.6%). Here, KRAS is linked to rectum adenocarcinoma.